AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
GLENMARK.NS

Glenmark Pharmaceuticals Limited (GLENMARK.NS) fair value

Healthcare · Drug Manufacturers - Specialty & Generic · NSE · India
₹2166.60-1.45%
Market cap ₹611.5BNext earnings 2026-07-31Updated Oct 24, 2026 · valuation updating
Our verdict
No fair value
We are missing the financial data our models need for this company. It will appear once the data arrives.
Not valued: there are no financial statements on file yet.
ACCE opinionGlenmark Pharmaceuticals Limited (GLENMARK.NS)
Fair value
Not available
ACCE price target
₹2225
Rating
Not rated
Horizon
12 months
ACCE price target published on 23 Oct 2026, 01:53 CEST.
Price used: ₹2167 at the close on 23 Oct 2026, 12:00 CEST.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
69
out of 100
P/E
34.5x
forward 22.3x
1-year return
+17.1%
Dividend yield
0.11%

Glenmark Pharmaceuticals Limited in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Glenmark Pharmaceuticals makes branded and generic specialty drugs, with a dermatology franchise and a respiratory business that includes inhaled products sold across the US, Europe and emerging markets. The gross margin of 71.9% points to a mix weighted toward specialty and differentiated products rather than commodity generics, which is the part of the business worth understanding before anything else. Revenue growth of 23.1% is the number that matters most here, and the question for a deeper look is how much of it is durable launch-driven growth versus one-off licensing or patent-cycle timing. At 22.7x forward earnings against a trailing 34.5x, the market is pricing in a sharp earnings recovery, so the margin path from a 15.7% operating base is the variable to test.

AI-assisted·How I use AIWritten Oct 23, 2026

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where GLENMARK.NS's valuation models land
Price
₹2166.60
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Recent performance

1 week
-2.7%
1 month
-12.5%
3 months
-1.2%
6 months
-5.8%
YTD
+6.9%
1 year
+17.1%

Recommendation history, last 12 months

DateTypeNewPreviousPrice
23 Oct 2026, 01:53 CESTACCE price target₹2225first publication₹2199

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

This security trades in INR. Exchange-rate movements can increase or reduce the result in your own currency.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full GLENMARK.NS page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth88Value46Quality87Momentum54Total69
Valuation
Trailing P/E
34.5x
Forward P/E
22.3x
PEG
0.04
P/B
no data
EV / Revenue
no data
Book value/sh
no data
Enterprise value
no data
Profitability
ROE
no data
FCF yield
no data
ROIC
no data
Health and risk
Debt / equity
0.06
Dividend yield
0.11%
Beta
no data

Price

+19.1% · 1Y

Ask anything about GLENMARK.NS

Answered from Glenmark Pharmaceuticals Limited fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 33% of peers
low 7.6x34.5xhigh 37.0x
Div yieldbetter than 17% of peers
low 0.0%0.1%high 3.2%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
GLENMARK.NS Glenmark Pharmaceuticals Limited₹2166.60--34.5x-8769
ALKEM.NS Alkem Laboratories Limited₹5013.50--27.4x-9153
ABBOTINDIA.NS Abbott India Limited₹25360.00--32.9x-9554
4506.T Sumitomo Pharma Co., Ltd.¥1904.00--7.6x38.5%8473
IPCALAB.NS Ipca Laboratories Limited₹1903.50--36.9x-9178
4151.T Kyowa Kirin Co., Ltd.¥2413.50--15.5x9.3%6870
4523.T Eisai Co., Ltd.¥5055.00--37.0x5.0%6360

Sector report card

Where GLENMARK.NS ranks against its sector peers on each metric.

Computing percentiles…